PACIRA BIOSCIENCES, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PACIRA BIOSCIENCES, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $457.00K.
- PACIRA BIOSCIENCES, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $2.00K.
- PACIRA BIOSCIENCES, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $490.00K.
- PACIRA BIOSCIENCES, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $12.00K.
- PACIRA BIOSCIENCES, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $502.00K.
- PACIRA BIOSCIENCES, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $1.94M, a 92.05% decline from fiscal 2022.
- PACIRA BIOSCIENCES, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $24.39M, a 2.32% increase from fiscal 2021.
- PACIRA BIOSCIENCES, INC. stock issued during period, value, stock options exercised for fiscal 2021 was $23.83M, a 47.30% decline from fiscal 2020.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $457.00K 10-Q · filed 2026-08-04 | $961.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $2.00K 10-Q · filed 2026-04-30 | |
| 2025-12-31 | $490.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $502.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $12.00K 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.94M 10-K · filed 2026-02-26 |
| 2023-09-30 | $25.00K 10-Q · filed 2024-11-06 | $2.83M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $1.58M 10-Q · filed 2024-07-30 | $4.37M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $334.00K 10-Q · filed 2024-05-07 | $13.64M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $889.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $24.39M 10-K · filed 2025-02-27 |
| 2022-09-30 | $1.56M 10-Q · filed 2023-11-02 | $28.29M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $10.86M 10-Q · filed 2023-08-02 | $29.75M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $11.08M 10-Q · filed 2023-05-03 | $24.12M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $4.79M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $23.83M 10-K · filed 2024-02-29 |
| 2021-09-30 | $3.02M 10-Q · filed 2022-11-03 | $28.03M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $5.22M 10-Q · filed 2022-08-03 | $49.59M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $10.80M 10-Q · filed 2022-05-04 | $52.57M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $8.99M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $45.23M 10-K · filed 2023-02-28 |
| 2020-09-30 | $24.58M 10-Q · filed 2021-11-03 | $39.71M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $8.20M 10-Q · filed 2021-08-03 | $16.54M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $3.46M 10-Q · filed 2021-05-04 | $10.37M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $3.47M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $8.47M 10-K · filed 2022-02-28 |
| 2019-09-30 | $1.41M 10-Q · filed 2020-10-30 | $7.69M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $2.03M 10-Q · filed 2020-08-06 | $9.26M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $1.56M 10-Q · filed 2020-05-07 | $8.31M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $7.17M 10-K · filed 2021-03-01 |
| 2018-09-30 | $2.98M 10-Q · filed 2019-11-08 | $5.95M derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-06-30 | $1.07M 10-Q · filed 2019-08-08 | $5.66M derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-03-31 | $419.00K 10-Q · filed 2019-05-02 | $6.34M derived: sum of 4 quarters · filed 2020-02-21 |
| 2017-12-31 | $1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $6.78M 10-K · filed 2020-02-21 |
| 2017-09-30 | $2.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $5.87M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $1.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $3.95M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $852.00K 10-Q · filed 2017-05-04 | $3.58M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $570.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $5.77M 10-K · filed 2019-02-28 |
| 2016-09-30 | $769.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | $6.47M derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-06-30 | $1.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $7.53M derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-03-31 | $3.04M 10-Q · filed 2016-05-02 | $9.07M derived: sum of 4 quarters · filed 2018-02-28 |
| 2015-12-31 | $1.27M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $10.07M 10-K · filed 2018-02-28 |
| 2015-09-30 | $1.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-27 | $10.30M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $2.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-30 | $10.86M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $4.05M 10-Q · filed 2015-04-30 | $9.32M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $7.24M 10-K · filed 2017-03-01 |
| 2014-09-30 | $2.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-30 | $6.54M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-06-30 | $1.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | $5.14M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-03-31 | $1.96M 10-Q · filed 2014-05-01 | $4.94M derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-12-31 | $813.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $3.86M 10-K · filed 2016-02-25 |
| 2013-09-30 | $979.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-31 | $3.28M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-06-30 | $1.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $2.45M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-03-31 | $877.00K 10-Q · filed 2013-05-08 | $1.49M derived: sum of 4 quarters · filed 2015-02-24 |
| 2012-12-31 | $237.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $770.00K 10-K · filed 2015-02-24 |
| 2012-09-30 | $150.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | $656.00K derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-06-30 | $230.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | $517.00K derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-03-31 | $153.00K 10-Q · filed 2012-05-09 | |
| 2011-12-31 | $123.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $135.00K 10-K · filed 2014-02-25 |
| 2011-09-30 | $11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-31 | |
| 2010-12-31 | $2.00K 10-K · filed 2013-03-07 | |
| 2009-12-31 | $3.00K 10-K · filed 2012-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |